Polarean Imaging Plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The firm manufactures, sells, and services hyperpolarizes and ancillary equipment for biomedical imaging research. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. It also develops and manufactures MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. The company was founded in 2011 and is headquartered in London, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company